Renaissance Technologies’s Aptevo Therapeutics APVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3
Closed -$6.58K 3553
2024
Q3
$6.58K Buy
+3
New +$13.8K ﹤0.01% 3474
2024
Q1
Sell
-1
Closed -$94K 3684
2023
Q4
$94K Buy
+1
New +$142K ﹤0.01% 3315
2023
Q3
Hold
0
3374
2023
Q2
Hold
0
3435
2023
Q1
Hold
0
3454
2022
Q4
Hold
0
3501
2022
Q3
Hold
0
3364
2022
Q2
Hold
0
3548
2022
Q1
Hold
0
3404
2021
Q4
Hold
0
3038
2021
Q3
Hold
0
2011
2021
Q2
Hold
0
1846
2021
Q1
Hold
0
1502
2020
Q4
Hold
0
1220
2020
Q3
Hold
0
2066
2020
Q2
Hold
0
2213
2020
Q1
Hold
0
2616
2019
Q4
Hold
0
2431
2019
Q3
Hold
0
2498
2019
Q2
Hold
0
2511
2019
Q1
Hold
0
2620
2018
Q4
Hold
0
2260
2018
Q3
Hold
0
1635
2018
Q2
Hold
0
1700
2018
Q1
Hold
0
2222
2017
Q4
Hold
0
2394
2017
Q3
Hold
0
3008
2017
Q1
Hold
0
-$47K 3209
2016
Q4
Hold
0
3166
2016
Q3
Hold
0
2726

Other funds holding APVO

Renaissance Technologies's APVO Position: Q4 2024 in Review

Renaissance Technologies sold out of Aptevo Therapeutics (APVO) in Q4 2024, closing a stake of 3 shares — an estimated $6.58K sold.

Renaissance Technologies first reported a position in APVO in Q4 2023 and held it in 2 quarters. The position peaked at $94K in Q4 2023. 7 funds tracked by Wall St. Rank hold APVO as of Q4 2024.

  • Renaissance Technologies reported no remaining Aptevo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Renaissance Technologies sold 3 Aptevo Therapeutics shares in Q4 2024, an estimated $6.58K.
  • Renaissance Technologies first reported a position in Aptevo Therapeutics in Q4 2023 and held it in 2 quarters.
  • Renaissance Technologies's Aptevo Therapeutics position peaked at $94K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.